PYC Therapeutics Past Earnings Performance
Past criteria checks 0/6
PYC Therapeutics's earnings have been declining at an average annual rate of -32.3%, while the Biotechs industry saw earnings growing at 13.2% annually. Revenues have been growing at an average rate of 52.4% per year.
Key information
-32.3%
Earnings growth rate
-26.1%
EPS growth rate
| Biotechs Industry Growth | 9.6% |
| Revenue growth rate | 52.4% |
| Return on equity | -47.0% |
| Net Margin | -171.0% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth
Apr 10
Is PYC Therapeutics (ASX:PYC) In A Good Position To Deliver On Growth Plans?
Nov 10We Think PYC Therapeutics (ASX:PYC) Needs To Drive Business Growth Carefully
Jul 03Here's Why We're Watching PYC Therapeutics' (ASX:PYC) Cash Burn Situation
Jan 25Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth
Jul 31We're Not Very Worried About PYC Therapeutics' (ASX:PYC) Cash Burn Rate
Mar 28Non-Executive Chair of the Board Alan Tribe Just Bought A Handful Of Shares In PYC Therapeutics Limited (ASX:PYC)
Feb 20
Have Insiders Been Selling PYC Therapeutics Limited (ASX:PYC) Shares?
Jan 26What You Need To Know About PYC Therapeutics Limited's (ASX:PYC) Investor Composition
Dec 22We Think PYC Therapeutics (ASX:PYC) Can Easily Afford To Drive Business Growth
Nov 17Revenue & Expenses Breakdown
How PYC Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 22 | -38 | 5 | 56 |
| 31 Mar 24 | 22 | -30 | 4 | 48 |
| 31 Dec 23 | 21 | -22 | 4 | 39 |
| 30 Sep 23 | 19 | -22 | 4 | 37 |
| 30 Jun 23 | 16 | -23 | 4 | 35 |
| 31 Mar 23 | 15 | -23 | 5 | 34 |
| 31 Dec 22 | 14 | -24 | 6 | 33 |
| 30 Sep 22 | 15 | -19 | 6 | 28 |
| 30 Jun 22 | 16 | -14 | 6 | 24 |
| 31 Mar 22 | 13 | -15 | 7 | 21 |
| 31 Dec 21 | 9 | -17 | 8 | 18 |
| 30 Sep 21 | 6 | -17 | 8 | 16 |
| 30 Jun 21 | 3 | -18 | 8 | 14 |
| 31 Mar 21 | 3 | -15 | 6 | 12 |
| 31 Dec 20 | 2 | -12 | 4 | 11 |
| 30 Sep 20 | 2 | -9 | 4 | 8 |
| 30 Jun 20 | 2 | -7 | 4 | 6 |
| 31 Mar 20 | 1 | -6 | 4 | 3 |
| 31 Dec 19 | 0 | -5 | 4 | 0 |
| 30 Sep 19 | 0 | -5 | 3 | 0 |
| 30 Jun 19 | 0 | -4 | 2 | 0 |
| 31 Mar 19 | 0 | -4 | 1 | 0 |
| 31 Dec 18 | 0 | -5 | 1 | 0 |
| 30 Sep 18 | 0 | -6 | 2 | 0 |
| 30 Jun 18 | 0 | -7 | 3 | 0 |
| 31 Mar 18 | 0 | -6 | 3 | 0 |
| 31 Dec 17 | 0 | -5 | 4 | 0 |
| 30 Sep 17 | 1 | -3 | 3 | 0 |
| 30 Jun 17 | 3 | -2 | 2 | 0 |
| 31 Mar 17 | 3 | -3 | 2 | 0 |
| 31 Dec 16 | 3 | -4 | 2 | 0 |
| 30 Sep 16 | 1 | -4 | 1 | 0 |
| 30 Jun 16 | 0 | -4 | 1 | 0 |
| 31 Mar 16 | 0 | -4 | 2 | 0 |
| 31 Dec 15 | 0 | -4 | 2 | 0 |
| 30 Sep 15 | 0 | -3 | 2 | 0 |
| 30 Jun 15 | 1 | -3 | 2 | 0 |
| 31 Mar 15 | 1 | -3 | 2 | 0 |
| 31 Dec 14 | 1 | -3 | 2 | 0 |
| 30 Sep 14 | 1 | -3 | 2 | 0 |
| 30 Jun 14 | 1 | -3 | 2 | 0 |
| 31 Mar 14 | 1 | -3 | 2 | 0 |
| 31 Dec 13 | 1 | -3 | 2 | 0 |
| 30 Sep 13 | 1 | -3 | 2 | 0 |
Quality Earnings: PYC is currently unprofitable.
Growing Profit Margin: PYC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PYC is unprofitable, and losses have increased over the past 5 years at a rate of 32.3% per year.
Accelerating Growth: Unable to compare PYC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PYC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: PYC has a negative Return on Equity (-47.02%), as it is currently unprofitable.